Cargando…

Down-regulation of PM20D1 is associated with clinical outcomes and prognosis of pregnant patients with diabetes mellitus

INTRODUCTION: The present study aimed to investigate the role of peptidase M20 domain containing 1 (PM20D1) in gestational diabetes mellitus (GDM). MATERIAL AND METHODS: This observational study included 189 cases of GDM patients who came to our department between March 2018 and December 2019. Addit...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Jie, Chen, Xiaohong, Xia, Jianqing, Zhang, Liemin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696964/
http://dx.doi.org/10.5114/aoms/136284
_version_ 1785154684978200576
author Hou, Jie
Chen, Xiaohong
Xia, Jianqing
Zhang, Liemin
author_facet Hou, Jie
Chen, Xiaohong
Xia, Jianqing
Zhang, Liemin
author_sort Hou, Jie
collection PubMed
description INTRODUCTION: The present study aimed to investigate the role of peptidase M20 domain containing 1 (PM20D1) in gestational diabetes mellitus (GDM). MATERIAL AND METHODS: This observational study included 189 cases of GDM patients who came to our department between March 2018 and December 2019. Additionally, 100 healthy pregnant individuals who came to physical examination were included as healthy controls during the same period. Western blotting was used to determine the expression of PM20D1 at gestational age 24-28 weeks and gestational age 37–40 weeks. Serum inflammatory factors of C-reactive protein (CRP), interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α, as well as leptin and adiponectin, were all measured by ELISA. The GDM related indices were also measured. RESULTS: The expression of PM20D1 was markedly decreased in GDM patients compared with the healthy controls. Patients in the third trimester of pregnancy (gestational age 37–40 weeks) showed significantly lower expression of PM20D1 than patients in the second trimester of pregnancy (gestational age 24-28 weeks). Serum levels of CRP, IL-1β, IL-6, TNF-α and leptin were remarkably higher and levels of adiponectin were markedly lower in GDM patients at both the second and third trimester of pregnancy. Also, levels of CRP, IL-1β, IL-6, TNF-α and leptin in GDM patients were the highest at the third trimester of pregnancy. Pearson’s analysis showed that PM20D1 was negatively correlated with IL-1β, IL-6 and leptin and was positively correlated with adiponectin. At the second trimester of pregnancy, patients with lower expression of PM20D1 showed remarkably higher levels of HOMA-IR, fasting insulin, FBG, OGTT-1hPG, OGTT-2hPG, TG and LDL-C, and showed markedly lower levels of HDL-C. Down-regulated PM20D1 predicted poor pregnancy outcomes. CONCLUSIONS: Reduced PM20D1 was associated with patients’ clinical outcomes and pregnancy outcomes in GDM.
format Online
Article
Text
id pubmed-10696964
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-106969642023-12-06 Down-regulation of PM20D1 is associated with clinical outcomes and prognosis of pregnant patients with diabetes mellitus Hou, Jie Chen, Xiaohong Xia, Jianqing Zhang, Liemin Arch Med Sci Clinical Research INTRODUCTION: The present study aimed to investigate the role of peptidase M20 domain containing 1 (PM20D1) in gestational diabetes mellitus (GDM). MATERIAL AND METHODS: This observational study included 189 cases of GDM patients who came to our department between March 2018 and December 2019. Additionally, 100 healthy pregnant individuals who came to physical examination were included as healthy controls during the same period. Western blotting was used to determine the expression of PM20D1 at gestational age 24-28 weeks and gestational age 37–40 weeks. Serum inflammatory factors of C-reactive protein (CRP), interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α, as well as leptin and adiponectin, were all measured by ELISA. The GDM related indices were also measured. RESULTS: The expression of PM20D1 was markedly decreased in GDM patients compared with the healthy controls. Patients in the third trimester of pregnancy (gestational age 37–40 weeks) showed significantly lower expression of PM20D1 than patients in the second trimester of pregnancy (gestational age 24-28 weeks). Serum levels of CRP, IL-1β, IL-6, TNF-α and leptin were remarkably higher and levels of adiponectin were markedly lower in GDM patients at both the second and third trimester of pregnancy. Also, levels of CRP, IL-1β, IL-6, TNF-α and leptin in GDM patients were the highest at the third trimester of pregnancy. Pearson’s analysis showed that PM20D1 was negatively correlated with IL-1β, IL-6 and leptin and was positively correlated with adiponectin. At the second trimester of pregnancy, patients with lower expression of PM20D1 showed remarkably higher levels of HOMA-IR, fasting insulin, FBG, OGTT-1hPG, OGTT-2hPG, TG and LDL-C, and showed markedly lower levels of HDL-C. Down-regulated PM20D1 predicted poor pregnancy outcomes. CONCLUSIONS: Reduced PM20D1 was associated with patients’ clinical outcomes and pregnancy outcomes in GDM. Termedia Publishing House 2021-05-09 /pmc/articles/PMC10696964/ http://dx.doi.org/10.5114/aoms/136284 Text en Copyright: © 2021 Termedia & Banach https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Clinical Research
Hou, Jie
Chen, Xiaohong
Xia, Jianqing
Zhang, Liemin
Down-regulation of PM20D1 is associated with clinical outcomes and prognosis of pregnant patients with diabetes mellitus
title Down-regulation of PM20D1 is associated with clinical outcomes and prognosis of pregnant patients with diabetes mellitus
title_full Down-regulation of PM20D1 is associated with clinical outcomes and prognosis of pregnant patients with diabetes mellitus
title_fullStr Down-regulation of PM20D1 is associated with clinical outcomes and prognosis of pregnant patients with diabetes mellitus
title_full_unstemmed Down-regulation of PM20D1 is associated with clinical outcomes and prognosis of pregnant patients with diabetes mellitus
title_short Down-regulation of PM20D1 is associated with clinical outcomes and prognosis of pregnant patients with diabetes mellitus
title_sort down-regulation of pm20d1 is associated with clinical outcomes and prognosis of pregnant patients with diabetes mellitus
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696964/
http://dx.doi.org/10.5114/aoms/136284
work_keys_str_mv AT houjie downregulationofpm20d1isassociatedwithclinicaloutcomesandprognosisofpregnantpatientswithdiabetesmellitus
AT chenxiaohong downregulationofpm20d1isassociatedwithclinicaloutcomesandprognosisofpregnantpatientswithdiabetesmellitus
AT xiajianqing downregulationofpm20d1isassociatedwithclinicaloutcomesandprognosisofpregnantpatientswithdiabetesmellitus
AT zhangliemin downregulationofpm20d1isassociatedwithclinicaloutcomesandprognosisofpregnantpatientswithdiabetesmellitus